Clinical Trial Update: VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating aflibercept (VEGF Trap) for recurrent malignant gliomas unresponsive to temozolomide has completed; results were posted on 2015-10-02.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Brain Tumor
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• VEGF Trap (aflibercept) (aflibercept)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 2 | Status: COMPLETED | Results posted: 2015-10-02